Phase 3 Readout~month

Phase 3 Topline: A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (Clemizole Hydr

Indication
Dravet Syndrome

Other upcoming events for HRMY

Phase 3 ReadoutPhase 3 Topline: Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Clemizole HCl as Adjunctive Thera
Patent ExpiryPatent/Exclusivity Expiry: WAKIX

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (Clemizole Hydr — HRMY Phase 3 Readout | BioSniper